Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure.

[1]  P Whelton,et al.  Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. , 1995, Hypertension.

[2]  S. Kivelä,et al.  Ambulatory blood pressure and left ventricular mass in older age , 2002, Scandinavian journal of clinical and laboratory investigation.

[3]  B. Waeber,et al.  Cardiovascular hypertrophy: role of angiotensin II and bradykinin. , 1996, Journal of cardiovascular pharmacology.

[4]  D. Levy,et al.  The spectrum of left ventricular hypertrophy in a general population sample: the Framingham Study. , 1987, Circulation.

[5]  R. Pini,et al.  Impact of Arterial Stiffening on Left Ventricular Structure , 2000, Hypertension.

[6]  M. Pfeffer,et al.  Pulsatile Hemodynamics in Congestive Heart Failure , 2001, Hypertension.

[7]  G Mancia,et al.  Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. , 1997, Circulation.

[8]  P. Okin,et al.  Prognostic implications of left ventricular hypertrophy. , 2001, American heart journal.

[9]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[10]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[11]  [Management of hypertensive patients with left ventricular hypertrophy]. , 2002, Presse medicale.

[12]  Giuseppe Mancia,et al.  Ambulatory Blood Pressure Is Superior to Clinic Blood Pressure in Predicting Treatment-Induced Regression of Left Ventricular Hypertrophy , 1997 .

[13]  J. C. Christiansen,et al.  Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. , 2020, Annals of internal medicine.

[14]  M. Nieminen,et al.  Effects of Losartan or Atenolol in Hypertensive Patients without Clinically Evident Vascular Disease: A Substudy of the LIFE Randomized Trial , 2003, Annals of Internal Medicine.

[15]  Left ventricular hypertrophy as a factor in arrhythmias and sudden death. , 1989, American journal of hypertension.

[16]  A. Hofman,et al.  Insulin resistance syndrome and left ventricular mass in an elderly population (The Rotterdam Study). , 1999, The American journal of cardiology.

[17]  S. Yusuf,et al.  Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril , 2001, Circulation.

[18]  J. Williamson,et al.  Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials , 2000, The Lancet.

[19]  J. Webster,et al.  The determinants of left ventricular hypertrophy defined by Sokolow–Lyon criteria in untreated hypertensive patients , 2003, Journal of Human Hypertension.

[20]  Yuling Hong,et al.  Sibling correlation of left ventricular mass and geometry in hypertensive African Americans and whites: the HyperGEN study. Hypertension Genetic Epidemiology Network. , 2001, American journal of hypertension.

[21]  R. Schmieder,et al.  Comparison of therapeutic studies on regression of left ventricular hypertrophy. , 1997, Advances in experimental medicine and biology.

[22]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[23]  S. Yusuf,et al.  Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. , 2000, Diabetes care.

[24]  D E Manyari,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[25]  M. Mariani,et al.  Blood pressure independent association of microalbuminuria and left ventricular hypertrophy in hypertensive men , 2003, Journal of internal medicine.

[26]  U. de Faire,et al.  Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures: A HOPE Substudy , 2001, Hypertension.

[27]  J. Fleg,et al.  Effects of Age and Aerobic Capacit on Arterial Stiffness in Healthy Adults , 1993, Circulation.

[28]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[29]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[30]  D. Levy,et al.  Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. , 1989, Annals of internal medicine.

[31]  E. Frohlich.  Hypertension, left ventricular hypertrophy, and coronary flow reserve. , 1997, Advances in experimental medicine and biology.

[32]  K. Weber.  Cardioreparation in Hypertensive Heart Disease , 2001, Hypertension.

[33]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[34]  A. Alexandrov,et al.  Cardiovascular Risk Factors and Sequelae in Hypertensive Children Identified by Referral Versus School-Based Screening , 2004, Hypertension.

[35]  K. Weber,et al.  Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones. , 1998, Annals of medicine.

[36]  W. Hundley,et al.  Relation of aortic distensibility determined by magnetic resonance imaging in patients > or =60 years of age to systolic heart failure and exercise capacity. , 2002, The American journal of cardiology.

[37]  S. Yusuf,et al.  Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. , 2000, Diabetes care.

[38]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[39]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[40]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[41]  F. Rengo,et al.  Relation between age, left ventricular mass and ventricular arrhythmias in patients with hypertension. , 1995, Journal of human hypertension.

[42]  M. Nieminen,et al.  Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study , 2003, Circulation.

[43]  J. Staessen,et al.  Overview of the outcome trials in older patients with isolated systolic hypertension , 1999, Journal of Human Hypertension.

[44]  R. Akdemir,et al.  Relation between stage of left ventricular diastolic dysfunction and QT dispersion , 2003, Acta cardiologica.

[45]  R J Glynn,et al.  Increased pulse pressure and risk of heart failure in the elderly. , 1999, JAMA.

[46]  W. Aronow,et al.  Association of Electrocardiographic Left Ventricular Hypertrophy with the Incidence of New Congestive Heart Failure , 1998, Journal of the American Geriatrics Society.

[47]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[48]  D. Levy,et al.  Trends in the Prevalence of Hypertension, Antihypertensive Therapy, and Left Ventricular Hypertrophy from 1950 to 1989 , 2000 .

[49]  R. Devereux,et al.  Linkage of Left Ventricular Contractility to Chromosome 11 in Humans: The HyperGEN Study , 2001, Hypertension.

[50]  J. Weiss,et al.  High Prevalence of Target Organ Damage in Young, African American Inner‐City Men With Hypertension , 2003, Journal of clinical hypertension.

[51]  Marc A Pfeffer,et al.  Determinants of Elevated Pulse Pressure in Middle-Aged and Older Subjects With Uncomplicated Systolic Hypertension: The Role of Proximal Aortic Diameter and the Aortic Pressure-Flow Relationship , 2003, Circulation.

[52]  Salim Yusuf,et al.  Blood-pressure reduction and cardiovascular risk in HOPE study , 2001, The Lancet.

[53]  J. Staessen,et al.  Mechanical and other factors relating to left ventricular hypertrophy. , 1994, Blood pressure. Supplement.

[54]  F. Morady,et al.  Norepinephrine--the myocardial hypertrophy hormone? , 1976, American heart journal.

[55]  M. Nieminen,et al.  Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study , 2003, Journal of hypertension.

[56]  Qin M. Chen,et al.  Apoptosis and Heart Failure , 2002, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[57]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[58]  K. Weber,et al.  Metabolic responses of extracellular matrix in tissue repair. , 1997, Annals of medicine.

[59]  Yuling Hong,et al.  Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study , 2002, Journal of hypertension.

[60]  M. Galderisi,et al.  Parental left ventricular hypertrophy predicts Doppler‐derived diastolic filling in young offspring of hypertensive subjects , 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[61]  R. Devereux,et al.  Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. , 2003, American journal of hypertension.

[62]  W. Hundley,et al.  Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. , 2002, JAMA.

[63]  F. Zannad,et al.  Clinical definition and epidemiology of advanced heart failure. , 1998, American heart journal.

[64]  M. Muiesan,et al.  Prognostic significance of left ventricular hypertrophy regression. , 1997, Advances in experimental medicine and biology.

[65]  Daniel Levy,et al.  Systolic Blood Pressure, Diastolic Blood Pressure, and Pulse Pressure as Predictors of Risk for Congestive Heart Failure in the Framingham Heart Study , 2003, Annals of Internal Medicine.

[66]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[67]  D. Levy,et al.  Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. , 1999, The New England journal of medicine.

[68]  J. Cohn.  Left ventricle and arteries: structure, function, hormones, and disease. , 2001, Hypertension.

[69]  T. Ichiki,et al.  Angiotensin II Type 2 Receptor Is Essential for Left Ventricular Hypertrophy and Cardiac Fibrosis in Chronic Angiotensin II–Induced Hypertension , 2001, Circulation.

[70]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[71]  E. J. Benjamin,et al.  Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. , 1995, Journal of the American College of Cardiology.

[72]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.